Diabetes Care, Vol 17, Issue 7 719-721, Copyright © 1994 by American Diabetes Association

ARTICLES

Long-term improvement of glycemic control by insulin treatment in NIDDM patients with secondary failure

T Lindstrom, P Eriksson, AG Olsson and HJ Arnqvist
Department of Internal Medicine, Faculty of Health Sciences, University Hospital, Linkoping, Sweden.

OBJECTIVE--To evaluate the long-term efficacy of insulin treatment of patients with non-insulin-dependent diabetes mellitus (NIDDM) and secondary failure to oral hypoglycemic agents. RESEARCH DESIGN AND METHODS--Twenty-one NIDDM patients with secondary failure were studied while they were still on oral agents. Then they were switched to insulin treatment, and after a median of 27 months, a long-term evaluation was conducted. RESULTS--At the long-term evaluation, metabolic control was still markedly improved by insulin treatment, with reduction of HbA1c from 8.8 +/- 0.2 (mean +/- SE) to 6.9 +/- 0.3% (P < 0.0001), lowering of very-low-density lipoprotein (VLDL) cholesterol concentration from 0.97 +/- 0.3 to 0.69 +/- 0.1 mM (P < 0.03), and lowering of total triglycerides from 2.8 +/- 0.6 to 1.8 +/- 0.3 mM (P < 0.005), mainly due to reduction of VLDL triglycerides. Body weight increased during the first year, but not thereafter (71.3 +/- 2.5 kg during oral treatment, 78.9 +/- 2.9 and 79.8 +/- 3.2 kg after 12 and 36 months of insulin treatment, respectively). Blood pressure did not change. Fasting and postprandial insulin concentrations increased, and C-peptide concentrations were lowered. CONCLUSIONS--Improvements of glycemic control and lipoprotein concentrations in patients with NIDDM and secondary failure persist also after insulin treatment for 2-3 years in spite of weight gain and hyperinsulinemia.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. C. Riddle and D. J. Drucker Emerging Therapies Mimicking the Effects of Amylin and Glucagon-Like Peptide 1 Diabetes Care, February 1, 2006; 29(2): 435 - 449. [Full Text] [PDF]

				R. G. Bretzel, S. Arnolds, J. Medding, and T. Linn A Direct Efficacy and Safety Comparison of Insulin Aspart, Human Soluble Insulin, and Human Premix Insulin (70/30) in Patients With Type 2 Diabetes Diabetes Care, May 1, 2004; 27(5): 1023 - 1027. [Abstract] [Full Text] [PDF]

				S. M. Strowig, M. L. Aviles-Santa, and P. Raskin Comparison of Insulin Monotherapy and Combination Therapy With Insulin and Metformin or Insulin and Troglitazone in Type 2 Diabetes Diabetes Care, October 1, 2002; 25(10): 1691 - 1698. [Abstract] [Full Text] [PDF]

				E. Larger, P. Rufat, D. Dubois-Laforgue, and S. Ledoux Insulin Therapy Does Not Itself Induce Weight Gain in Patients With Type 2 Diabetes Diabetes Care, October 1, 2001; 24(10): 1849 - 1850. [Full Text] [PDF]

				H. Yki-Jarvinen, L. Ryysy, M. Kauppila, E. Kujansuu, J. Lahti, T. Marjanen, L. Niskanen, S. Rajala, S. Salo, P. Seppala, et al. Effect of Obesity on the Response to Insulin Therapy in Noninsulin-Dependent Diabetes Mellitus J. Clin. Endocrinol. Metab., December 1, 1997; 82(12): 4037 - 4043. [Abstract] [Full Text] [PDF]